Therapeutic preparation for kidney disease

By optimizing the combination dosing regimen of repamengerum or propamengerum with AT1R blockers, the problem of unclear dosing in the prior art has been solved, and the therapeutic effect of CCR2-AT1R complex has been improved, especially in the application of kidney disease.

CN118924785APending Publication Date: 2024-11-12DIMERIX BIOSCIENCES PTY LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202310747837.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-05-12
Filing Date
2023-06-25
Publication Date
2024-11-12

AI Technical Summary

Technical Problem

In the prior art, the dosing regimens of repafenone and propafenone with AT1R blockers are unclear, and the affinity of AT1R blockers in the CCR2-AT1R complex does not match their affinity for AT1R alone, affecting the therapeutic effect.

Method used

Combinations of repafenone or propafenone with an AT1R blocker are available at daily doses of 200 mg to 280 mg, the AT1R blocker having an affinity for the CCR2-AT1R complex equal to or greater than that for AT1R alone, for the treatment of kidney disease.

Benefits of technology

By optimizing the dosing regimen and selecting appropriate AT1R blockers, the therapeutic effect of the CCR2-AT1R complex was improved, thus enhancing its efficacy in treating kidney diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004300308410000251
    Figure BDA0004300308410000251
  • Figure BDA0004300308410000261
    Figure BDA0004300308410000261
  • Figure BDA0004300308410000291
    Figure BDA0004300308410000291
Patent Text Reader

Abstract

The present invention provides therapeutic formulations suitable for the delivery of daily doses of reparigermanium or proparigermanium, optionally in combination with an AT1R blocker, and the use of such therapeutic formulations for the treatment of kidney disease.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to therapeutic preparations containing rapagermanium or propagermanium and methods of use thereof, and therapeutic preparations containing AT1R blockers and methods of use thereof. Rapagermanium or propagermanium can be delivered with AT1R blockers in a therapeutic combination regimen. Background Art

[0002] Therapies based on chemokine receptor 2 (CCR2) pathway inhibitors or AT1R blockers, optionally in a therapeutic combination regimen, for diseases such as renal and respiratory diseases are known.

[0003] Repagermanium or propagermanium can be used as CCR2 pathway inhibitors. Repagermanium and propagermanium have been described as polymer compounds in previous literature. The bulk drug 3-[(2-carboxyethyl-oxygermyl)oxy-oxygermyl]propionic acid exhibits polymorphism and can exist in different solid forms. However, the inventors did not observe any pharmacological effects of Repagermanium polymerization during the manufacture or testing of the bulk drug.

[0004] Polymorphs of 3-[(2-carboxyethyl-oxygermyl)oxy-oxygermyl]propionic acid include rapagem, propagemyl, promaline, Ge-132, germanium sesquioxide, 2-carboxyethylgermanium sesquioxide, SK-818, and bis(2-carboxyethylgermanium) sesquioxide.

[0005] The two most characterized solid forms, rapagermanium and propagermanium, have a common core structure (Mizuno, et al, 2015). The two APIs have different International Nonproprietary Names (INNs), INN#6259 for rapagermanium and INN#6260 for propagermanium. They consist of differently packed monomer molecules, 3-[(2-carboxyethyl-oxygermyl)oxy-oxygermyl]propionic acid, which vary in the structural units coordinated by H bonds. X-ray diffraction results show that rapagermanium has an infinite sheet structure, which is significantly different from the ladder-like structure of propagermanium polymers composed of tandem eight-membered rings composed of Ge-O bonds. In solid form, rapagermanium and propagermanium are different; however, in solution, when the structural units are dissolved, they are the same.

[0006] The angiotensin type 1 receptor (AT1R, angiotensin II receptor type 1) is a G protein-coupled receptor. With respect to their effects on AT1R blockade, AT1R blockers have traditionally been considered therapeutically interchangeable despite their structural differences.

[0007] However, for various diseases, the dosing regimen of rapagermanium or propagermanium and AT1R blockers remains to be clearly determined. It is necessary to establish a suitable dosing regimen for rapagermanium or propagermanium and AT1R blockers; or at least provide a new dosing regimen to supplement the previously known dosing regimens. The present invention aims to provide an improved or alternative dosing regimen for rapagermanium or propagermanium and AT1R blockers. rapagermanium or propagermanium can be delivered with AT1R blockers in a therapeutic combination regimen.

[0008] The foregoing discussion of the background art is intended only to facilitate understanding of the present invention. The discussion is not an acknowledgement or admission that any of the material referred to is or was ever part of the common general knowledge as at the priority date of the application. Summary of the invention

[0009] The present invention provides therapeutic formulations suitable for delivering a daily dose of 200 mg to 280 mg of rapagermanium or propagermanium.

[0010] The present invention also provides therapeutic formulations suitable for delivering a daily dose of a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0011] The present invention also provides therapeutic formulations suitable for delivering a daily dose of: (a) a therapeutically effective amount of rapagermanium or propagermanium; and (b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0012] Preferably, the daily dosage of rapagermanium or propagermanium is 200 mg to 280 mg.

[0013] Preferably, the AT1R blocker is selected from the list consisting of candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, valsartan and sparsentan.

[0014] Preferably, the daily dose of the AT1R blocker is 2 mg to 800 mg.

[0015] The present invention also provides a dosing regimen comprising administering a daily dose of 200 mg to 280 mg of rapagermanium or propagermanium.

[0016] The present invention also provides a dosing regimen comprising administering a daily dose of a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0017] The present invention also provides a dosing regimen comprising administering a daily dose of: (a) a therapeutically effective amount of rapagermanium or propagermanium; and (b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0018] The present invention also provides a method for treating, improving or preventing kidney disease, comprising the following steps: administering to a subject (a) a therapeutic formulation suitable for delivering 200 mg to 280 mg of rapagermanium or propagermanium per day.

[0019] The present invention also provides a method for treating, improving or preventing kidney disease, comprising the following steps: administering to a subject (a) a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0020] The present invention also provides a method for treating, improving or preventing kidney disease, comprising the following steps: administering to a subject (a) a therapeutically effective amount of rapagermanium or propagermanium per day; and (b) a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0021] The present invention also provides a use of 200 mg to 280 mg of rapagermanium or propagermanium per day for manufacturing a preparation for treating, improving or preventing kidney diseases in a subject.

[0022] The present invention also provides a use of 200 mg to 280 mg of propagermanium per day for treating, improving or preventing kidney diseases in a subject.

[0023] The present invention also provides the use of a therapeutically effective amount of an AT1R blocker for manufacturing a preparation for treating, improving or preventing kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0024] The present invention also provides a use of a therapeutically effective amount of an AT1R blocker for treating, ameliorating or preventing kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0025] The present invention also provides the use of (a) a therapeutically effective amount of rapagermanium or propagermanium, and (b) a therapeutically effective amount of an AT1R blocker for manufacturing a preparation for treating, improving or preventing a kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0026] The present invention also provides the use of (a) a therapeutically effective amount of rapagermanium or propagermanium, and (b) a therapeutically effective amount of an AT1R blocker for treating, ameliorating or preventing a kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0027] The present invention also provides a therapeutically effective amount of rapagermanium or propagermanium for use in a preparation for treating, ameliorating or preventing kidney disease in a subject, wherein rapagermanium is administered to the subject simultaneously or sequentially with a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0028] The present invention also provides a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone, which is used in a preparation for treating, improving or preventing kidney disease in a subject, wherein at least one AT1R blocker is administered to the subject simultaneously or sequentially with rapagemator or propagemator.

[0029] The present invention also provides a kit for treating or preventing kidney disease in a subject, the kit comprising: (a) a daily dose of 200 mg to 280 mg of rapagermanium or propagermanium; and (b) instructions for use.

[0030] The present invention also provides a kit for treating or preventing kidney disease in a subject, the kit comprising: (a) a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone; and (b) instructions for use.

[0031] The present invention also provides a kit for treating or preventing kidney disease in a subject, the kit comprising: (a) a therapeutically effective amount of rapagermanium or propagermanium; (b) a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone; and (c) instructions for use.

[0032] Preferably, repagermanium or propagermanium is provided in a daily dosage of 200 mg to 280 mg repagermanium or propagermanium.

[0033] Preferably, the AT1R blocker is selected from the list consisting of candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, valsartan and sparsentan.

[0034] Preferably, the subject to be treated is a human mammal.

[0035] Preferably, the renal disease is a renal disease associated with proteinuria.

[0036] Preferably, the renal disease is selected from the list comprising focal segmental glomerulosclerosis (FSGS; including idiopathic (primary) FSGS, secondary FSGS, hereditary FSGS and FSGS due to any other cause), renal fibrotic disorders, immunoglobulin A nephropathy (IgAN), Alport syndrome, chronic kidney disease including chronic kidney disease caused by diabetic nephropathy, renal insufficiency (diabetic and non-diabetic), and renal failure conditions including diabetic nephropathy, glomerulonephritis, scleroderma, glomerulosclerosis, proteinuria in primary renal disease and renovascular hypertension.

[0037] Preferably, the AT1R blocker is not EXP3174. BRIEF DESCRIPTION OF THE DRAWINGS

[0038] Other features of the invention are more fully described in the following description of several non-limiting embodiments. This description is included only for the purpose of illustrating the invention. It should not be construed as a limitation on the broad overview, disclosure or description of the invention described above. This description will be made with reference to the accompanying drawings, in which:

[0039] Figure 1 This is a graph showing the effect of different doses of Repagermanium on the therapeutic efficacy. The efficacy of Repagermanium doses presents a "bell-shaped" inhibition curve.

[0040] Figure 2 is a graph comparing the potency of ARBs at AT1R alone and at the relevant points of potency in inhibiting G protein dissociation from the co-stimulatory CCR2-AT1R complex. Cand; Candesartan, CandC; Candesartan cilexetil, Epro; Eprosartan, EXP; EXP3174, Irb; Irbesartan, Fim; Fimasartan*, Los; Losartan, Olm; Olmesartan, OlmM; Olmesartan medoxomil, Spar; Sparsentan, Tel; Telmisartan, Val; Valsartan.

[0041] Figure 3Graph showing statistical analysis of EXP3174 potency (pIC50) at AT1R alone versus potency in inhibiting G protein dissociation from the co-stimulatory CCR2-AT1R complex. **, p<0.01 as measured by one-sample t-test.

[0042] Figure 4 is a graph of the effect of ARB, CCR2, or ARB+CCR2 inhibition on the dissociation of the G protein (Gαi1-luciferase) from the co-stimulatory CCR2-AT1R complex.

[0043] Figure 5 is a plot comparing the potency of ARBs at AT1R alone with the potency in inhibiting G protein dissociation from the co-stimulatory CCR2-AT1R complex in the presence of rapamermanium*. Cand; Candesartan, CandC; Candesartan cilexetil, Epro; Eprosartan, EXP; EXP3174; Fim; Fimasartan*, Irb; Irbesartan, Los; Losartan, Olm; Olmesartan, OlmM; Olmesartan medoxomil, Spar; Sparsentan, Tel; Telmisartan, Val; Valsartan.

[0044] Description of the invention DETAILED DESCRIPTION OF THE INVENTION

[0046] While CCR2 inhibitors and / or AT1R blockers have been used in a variety of therapeutic settings, much remains unknown regarding dosing regimens that provide effective therapeutic outcomes.

[0047] preparation

[0048] The present invention provides a therapeutic formulation comprising: (i) rapagem or propagemator suitable for delivery at 200 mg to 280 mg per day; (ii) an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone; or (iii) rapagem or propagemator suitable for delivery at 200 mg to 280 mg per day and an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0049] Repagermanium or propagermanium preparations

[0050] The present inventors have surprisingly discovered that the doses of propagermanium or germanium required for therapeutic efficacy fall within a narrow dosage and treatment regimen.

[0051] Repagermanium and propagermanium blocked pathways associated with MCP-1-induced migration, monocyte activation, and chemotactic migration. Repagermanium and propagermanium also blocked the function of cellular structures involved in chemotaxis, such as microfilaments, microtubules, and intermediate filaments, and surface proteins, such as glycosylphosphatidylinositol (GPI)-anchored proteins, more specifically, CD55, CD59, and CD16.

[0052] The INN of rapagermanium is INN# 6259 and propagermanium is INN# 6260. Propagermanium has been used as an active agent for chronic hepatitis and has been shown to specifically inhibit the in vitro chemotactic migration of monocytes through MCP-1 by a mechanism that appears to require glycosylphosphatidylinositol (GPI) anchored proteins such as CD55, CD59 and CD16 (Yokochi, S. (2001) Journal of Interferon and Cytokine Research 21: 389-398). Other names for propagermanium and / or ripagermanium include 3-[(2-carboxyethyl-oxygermyl)oxy-oxygermyl] propionic acid, proxigermanium, Ge-132, bis(2-carboxyethylgermanium) sesquioxide (CEGS), 2-carboxyethylgermasesquioxane, SK-818, organic germanium, germanium sesquioxide, 3,3'-(1,3-dioxo-1,3-digermanoxanediyl)dipropionic acid, 3-oxygermylpropionic acid polymer, and poly-trans-(2-carboxyethyl)germanium. In the present invention, the term "ripagermanium" is defined to include "propagermanium".

[0053] The inventors have found that a dose of, for example, 80 mg twice a day causes the blood concentration of Repagermanium or Propagermanium to drop too low before the next dose to provide therapeutic efficacy. In addition, contrary to expectations, a dose of, for example, 160 mg twice a day causes a decrease in therapeutic efficacy. Thus, at moderate doses, the therapeutic efficacy of Repagermanium or Propagermanium is greatest. This general trend is seen in Figure 1 .

[0054] Thus, the present invention provides therapeutic formulations suitable for delivering daily doses of 200 mg to 280 mg of rapagermanium or propagermanium.

[0055] The present invention also provides a dosing regimen, comprising administering a daily dose of 200 mg to 280 mg of rapagermanium or propagermanium.

[0056] Repagermanium or propagermanium may be suitable for delivery at 220 mg to 260 mg per day, more preferably 240 mg per day.

[0057] Preferably, the preparation containing rapagem or propagem is delivered twice a day (BID). Therefore, the preparation can be used for a dosage regimen, preferably including rapagem or propagem in a dosage of 100 mg to 140 mg twice a day. Although a dosage regimen of three or more times a day is desired, it is unlikely that the subject receiving treatment will accept and adhere to the dosage regimen. If 3 or more administrations are performed every day, the total daily dose should still be 200 mg to 280 mg every day, more preferably 240 mg every day.

[0058] If rapagem or propagem can be administered to children under 12 years of age, a proportional dose can be administered to achieve the same exposure and pharmacokinetic results as the adult dose. The proportional dose is preferably determined based on weight. The adult dose of 200 mg to 280 mg rapagem per day is based on an average adult of 70 kg. For children under 12 years of age, the dose can be calculated based on their 70 kg body weight ratio.

[0059] Based on pharmacokinetic data, in particular the half-lives of rapagermanium and propagermanium in vivo and the C max , a therapeutic preparation containing propagermanium or propagermanium of the present invention has been developed.

[0060] This specific dose and exposure of propagermanium or rapagermanium is based on the assumption that reduced chemotaxis of CCR2-expressing cells is necessary to achieve peak therapeutic effect.

[0061] Angiotensin type 1 receptor blocker activity

[0062] The present invention surprisingly discovered that while AT1R blockers have traditionally been considered interchangeable, there are some exceptions based on the interaction of AT1R blockers and the CCR2-AT1R complex.

[0063] Angiotensin type 1 receptor (AT1R, AT1R, angiotensin II receptor type 1) is a G protein-coupled receptor.

[0064] The phrase "angiotensin type 1 receptor inhibitor" (also known as angiotensin receptor blocker or ARB) is understood to mean an agent or compound that can inhibit or partially inhibit AT1R activation. This includes AT1R antagonists, inverse agonists and negative allosteric modulators.

[0065] The term "AT1R blocker" includes pharmaceutically acceptable salts of the AT1R blocker. Alternatively, the AT1R blocker may be an antibody blocker of AT1R.

[0066] For example, the AT1R blocker may be selected from the group consisting of: irbesartan (eg ), eprosartan (such as ), losartan (such as ), valsartan (such as ), telmisartan (such as ), candesartan (such as ), Olmesartan (such as ), Azilsartan (such as ), sparsentan (such as Filspari), fimasartan (such as ) and ZD-7115. For example, the angiotensin receptor inhibitor may be irbesartan or valsartan.

[0067] Taylor et al. (2011) (Journal of American Society of Hypertension 13(9):677-686) reviewed angiotensin II AT1 receptor blockers (also called AT1R blockers or ARBs) and noted that "there are no major differences in efficacy or other clinical characteristics among the older drugs in this class." Notably, the differences in characteristics appear to be related to interactions with other pathways rather than core angiotensin II AT1 receptor blockade. Taylor reported that although "there are some pharmacological differences among ARBs, and some drugs in this class have specific effects independent of angiotensin II receptor blockade, there is currently no strong evidence that these effects translate into unique protection against target organ damage caused by hypertension." Therefore, with respect to their effects on AT1R blockade, ARBs are functionally interchangeable despite their structural differences.

[0068] As Taylor noted in the first paragraph, ARBs were first commercialized in the 1990s, and eight specific ARBs are cited as available in the United States. Despite the longer use of this class of drugs, physicians appear to view them as a largely interchangeable group. While there are some specific subtleties in the exact pharmacology of some groups, these do not appear to be related to their angiotensin II AT1 receptor activity. Furthermore, all pharmacological products exhibit subtle differences in some patients, but variations in some subgroups do not preclude them from being generally useful in treatment.

[0069] AT1R blockers preferably inhibit or partially inhibit AT1R. Preferably, AT1R blockers interact directly with AT1R and exclude therapeutic drugs such as angiotensin converting enzyme inhibitors (ACEi) therapeutic drugs, which act upstream of AT1R to prevent the production of functional ligands but do not interact with AT1R itself.

[0070] The term "AT1R blocker" includes pharmaceutically acceptable salts of the AT1R blocker. Alternatively, the AT1R blocker may be an antibody blocker of AT1R.

[0071] For example, the angiotensin receptor inhibitor may be irbesartan. Irbesartan is an angiotensin type 1 receptor antagonist, also known as 2-butyl-3-({4-[2-(2H-1,2,3,4-tetrazolyl-5-yl)phenyl]phenyl}methyl)-1,3-diazaspiro[4.4]non-1-en-4-one. The angiotensin receptor inhibitor may be sparsentan. Sparsentan, also known as 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-N-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide, is a combined selective antagonist of angiotensin II type 1 receptor (AT1R) and endothelin A receptor.

[0072] The CCR2-AT1R complex has previously been identified as a therapeutic target for kidney and other diseases. The inventors have previously demonstrated that AT1R-CCR2 heteromers with ARBs consistently and highly inhibit inositol phosphate signaling. They have also demonstrated that the CCR2-AT1R complex leads to activation of Gαi proteins and recruitment of β-arrestin.

[0073] However, it is unclear whether ARBs retain potency to inhibit Gαi activation or recruit β-arrestin when acting at the CCR2-AT1R complex compared to AT1R alone. This is important because inhibition of AT1R by ARBs is required for clinical efficacy. In Gαi dissociation assays, the potency of ARBs at AT1R alone has generally been found to correlate well with the potency of ARBs at costimulating CCR2-AT1R complexes.

[0074] However, surprisingly, compound EXP3174 was found to be less potent than expected at the CCR2-AT1R complex than at AT1R alone. Therefore, the AT1R blocker EXP3174 is less effective than other AT1R blockers when the AT1R-CCR2 complex is present. This suggests that the affinity of ARBs for the CCR2-AT1R complex is not distinct. ARBs with lower potency at the CCR2-AT1R complex than at AT1R alone may have reduced clinical efficacy.

[0075] The AT1R blocker EXP3174 is a metabolite of losartan that has been used extensively in research and is reported to be significantly more effective than losartan in blocking angiotensin II-induced cellular responses (Sachinidis et al. (1993) EXP3174, a metabolite of losartan (MK 954, DuP 753) is more potent than losartan in blocking the angiotensin II-induced responses in vascular smooth muscle cells J Hypertens 11(2): 155-62). EXP3174 was used in WO2012094703 as an experimental AT1R blocker in combination with a CCR2 pathway inhibitor.

[0076] Thus, the present invention provides a formulation comprising a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0077] For purposes of the present invention, equal or greater affinity of an AT1R blocker for a CCR2-AT1R complex is considered an AT1R blocker affinity, wherein the affinity loss at the CCR2-AT1R complex does not exceed 3.5-fold compared to the affinity at AT1R.

[0078] The present invention also provides a dosing regimen comprising administering a daily dose of a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0079] Preferably, the AT1R blocker is selected from the list consisting of: candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, valsartan and sparsentan. Preferably, the AT1R blocker is not EXP3174.

[0080] If the affinity of the AT1R blocker for the CCR2-AT1R complex is lower than for AT1R alone, the experimental results for establishing the dose may not translate to the clinical setting. The therapeutic dose of an AT1R blocker with a lower affinity for the CCR2-AT1R complex compared to AT1R alone will be higher than the dose expected and established in the experimental setting using only AT1R alone, because in the subject, the AT1R is presented as a CCR2-AT1R complex. Therefore, more AT1R blockers with a lower affinity for the CCR2-AT1R complex compared to AT1R alone will be needed to achieve the same therapeutic efficacy in vivo.

[0081] Preferably, the AT1R blocker is provided at 2 mg to 800 mg per day, provided in one or more doses. More preferably, the AT1R blocker is provided at 5 mg to 320 mg per day. For example, the AT1R blocker is irbesartan, administered at a dose of 75, 150 or 300 mg per day, provided in one or more doses. Alternatively, the AT1R blocker is valsartan, administered at a dose of 80 mg, 160 mg or 320 mg per day, provided in one or more doses.

[0082] As noted above, as described by Taylor et al. (2011), AT1R blockers are functionally interchangeable, although the dosages of each activity differ. The skilled artisan will use their knowledge of the dosage range for each AT1R blocker to determine the appropriate dosage for use in the present invention.

[0083] Table 1: Recommended daily doses of AT1R blockers

[0084] ARB Daily dose Irbesartan 50-300mg Valsartan 30-320 mg Losartan 10-100 mg Candesartan 2-32 mg Telmisartan 10-80 mg Olmesartan 5-40 mg Eprosartan 300-800mg Azilsartan 10-80 mg Fimasartan 30-120 mg

[0085] Combination preparations

[0086] Without being bound by any theory, it is proposed that inhibition of the CCR2 pathway as well as AT1R signaling is preferred for clinical effectiveness. Therefore, a combination of a CCR2 pathway inhibitor and an ARB with an affinity for the CCR2-AT1R complex equal to or greater than the affinity for AT1R alone is preferred.

[0087] Examples of such combinations include combinations of rapagermanium or propagermanium with the ARB drugs candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, and valsartan, and the dual ARB endothelin receptor antagonist sparsentan. These combinations do not include combinations of rapagermanium or propagermanium with EXP3174.

[0088] The present invention also provides formulations suitable for delivering:

[0089] a) a therapeutically effective amount of rapagermanium or propagermanium; and

[0090] b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0091] The present invention also provides formulations suitable for delivering:

[0092] a) 200 mg to 280 mg per day of rapagermanium or propagermanium; and

[0093] b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0094] The present invention also provides a dosing regimen comprising administering a daily dose of:

[0095] a) 200 mg to 280 mg of rapagermanium or propagermanium;

[0096] b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0097] The present invention also provides a dosing regimen comprising administering a daily dose of:

[0098] c) 200 mg to 280 mg of rapagermanium or propagermanium;

[0099] d) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0100] AT1R blockers having an affinity for the CCR2-AT1R complex equal to or greater than the affinity for AT1R alone may be selected from the list consisting of candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, valsartan and sparsentan. Preferably, the AT1R blocker is not EXP3174.

[0101] For purposes of the present invention, equal or greater affinity of an AT1R blocker for a CCR2-AT1R complex is considered an AT1R blocker affinity, wherein the affinity loss at the CCR2-AT1R complex does not exceed 3.5-fold compared to the affinity at AT1R.

[0102] The therapeutically effective amount of the above AT1R blocker is preferably 2 mg to 800 mg per day.

[0103] The above-mentioned pharmaceutical preparations may optionally contain excipients, solvents, carriers and other pharmaceutically acceptable ingredients.

[0104] The term "component" as used in the context of the pharmaceutical formulation of the present invention refers to an AT1R blocker or repagermanium.

[0105] As used herein, the term "inhibit" means a decrease below the detectable limit when compared to a reference substance. The phrase includes preventing, delaying or hindering an action to prevent an undesirable result.

[0106] As used herein, the term "partial inhibition" means any reduction within detectable limits when compared to a reference. The phrase includes preventing, delaying or hindering an action to prevent an undesirable result.

[0107] Repagermanium and the AT1R blocker can be the same active agent, such as a bispecific antibody.

[0108] Both AT1R blockers and rapagermanium can be pharmaceutically acceptable salts of their respective active agents. Pharmaceutically and veterinarily acceptable salts include salts that maintain the biological effectiveness and properties of the compounds disclosed herein and are not biologically or otherwise unfavorable. In many cases, the compounds disclosed herein are capable of forming acidic and / or basic salts through the presence of amino and / or carboxyl groups or groups similar thereto. Acceptable base addition salts can be prepared from inorganic and organic bases. By way of example only, salts derived from inorganic bases include sodium, potassium, lithium, ammonium, calcium and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines such as, by way of example only, alkylamines, dialkylamines, trialkylamines, substituted alkylamines, di(substituted alkyl)amines, tri(substituted alkyl)amines, alkenylamines, dienylamines, trialkenylamines, substituted alkenylamines, di(substituted alkenyl)amines, tri(substituted alkenyl)amines, cycloalkylamines, di(cycloalkyl)amines, tri(cycloalkyl)amines, substituted cycloalkylamines, disubstituted cycloalkylamines, trisubstituted cycloalkylamines, cycloalkenylamines, di(cycloalkyl)amines, The invention also includes amines comprising cycloalkenyl)amines, tri(cycloalkenyl)amines, substituted cycloalkenylamines, disubstituted cycloalkenylamines, trisubstituted cycloalkenylamines, arylamines, diarylamines, triarylamines, heteroarylamines, diheteroarylamines, triheteroarylamines, heterocyclylamines, diheterocyclylamines, triheterocyclylamines, mixed di- and tri-amines, wherein at least two of the substituents on the amine are different and are selected from alkyl, substituted alkyl, alkenyl, substituted alkenyl, cycloalkyl, substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, aryl, heteroaryl, heterocyclyl, and the like. Also included are amines wherein two or three substituents together with the amino nitrogen form a heterocyclyl or heteroaryl group.

[0109] Pharmaceutically and veterinarily acceptable acid addition salts can be prepared from inorganic and organic acids. By way of example only, inorganic acids that can be used include hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like. By way of example only, organic acids that can be used include acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.

[0110] Pharmaceutically or veterinarily acceptable salts of the compounds of the present disclosure can be synthesized by conventional chemical methods from parent compounds containing a basic or acidic moiety. Typically, such salts can be prepared by reacting the free acid or base form of these compounds with a stoichiometric amount of an appropriate base or acid in water or an organic solvent or in a mixture of the two; typically, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol or acetonitrile are preferred. A list of suitable salts is found in Remington's Pharmaceutical Sciences. 17th edition, Mack Publishing Company, Easton, Pa. (1985), p. 1418, the disclosure of which is incorporated herein by reference. Examples of such acceptable salts are iodide, acetate, phenylacetate, trifluoroacetate, acrylate, ascorbate, benzoate, chlorobenzoate, dinitrobenzoate, hydroxybenzoate, methoxybenzoate, methylbenzoate, o-acetoxybenzoate, naphthalene-2-benzoate, bromide, isobutyrate, phenylbutyrate, gamma-hydroxybutyrate, beta-hydroxybutyrate, butyne-1,4-dioate, hexyne-1,4-dioate, hexyne-1,6-dioate, caproate, octanoate, chloride, cinnamate, citrate, decanoate, formate, fumarate, glycolate, heptanoate, hippurate, lactate, malate, maleate, The salts described herein are bis(2-hydroxyethylsulfonate, ...

[0111] Symptom or disease

[0112] In general, a range of ailments associated with chemokines can be treated by the methods of the present invention. This includes ailments associated with increased or decreased chemokine production, and / or increased or decreased responsiveness of cells to chemokines. Chemokine-related ailments are also understood to be diseases or conditions in which chemokine receptors display abnormal characteristics, chemokine receptors are targets of specific pathogens, or chemokine receptors are targets of drug intervention.

[0113] The disease associated with chemokines is preferably an inflammatory disorder, or a disorder arising from or associated with inflammation. The inflammatory disorder, or a disorder arising from or associated with inflammation may be a kidney disease.

[0114] Inflammatory disorders or disorders derived from inflammation to be treated, improved or prevented or disorders associated with inflammation to be treated, improved or prevented are preferably renal diseases. More preferably, renal diseases are renal diseases associated with proteinuria. Renal diseases can be selected from the following list including: focal segmental glomerulosclerosis (FSGS; including idiopathic (primary) FSGS, secondary FSGS, hereditary FSGS and FSGS caused by any other reason), renal fibrosis disorders, immunoglobulin A nephropathy (IgAN), Alport syndrome, chronic kidney disease, including chronic kidney disease caused by diabetic nephropathy, renal insufficiency (diabetic and non-diabetic), and renal failure symptoms, including diabetic nephropathy, glomerulonephritis, scleroderma, glomerulosclerosis, proteinuria and renovascular hypertension of primary kidney disease.

[0115] The term "prevention" includes administering the formulations of the invention to subjects who have symptoms indicating that they are at risk of developing a kidney disease as described above, but who may not have been diagnosed with a kidney disease at the time of treatment. For example, a subject may have elevated blood creatine or urine protein, but has not yet been diagnosed with a kidney disease.

[0116] The term "ameliorating" includes administering the formulation of the invention to a subject who already has kidney disease and is at risk of developing post-disease symptoms.

[0117] Measurement of inhibition

[0118] Inhibition or partial inhibition of the CCR2 pathway and / or AT1R caused by (i) rapagen or propagen, (ii) an AT1R blocker, or (iii) a combination of rapagen or propagen and an AT1R blocker can be measured using the in vitro methods listed herein and include, but are not limited to, biochemical or cellular assays for assessing in vitro chemotactic migration of neutrophils expressing CCR2 and other cells known in the art, as well as measuring inositol phosphate generation, extracellular regulated kinase (ERK) phosphorylation, cAMP generation, label-free techniques (such as using impedance, photorefraction or charge redistribution), G protein coupling using proximity reporter systems or other methods, β-arrestin recruitment or mediated signaling, transcription factor-based reporter systems, microscopic visualization using fluorescent labels, assessment of receptor cellular localization using antibodies (such as enzyme-linked immunosorbent assay), assessment of cellular localization and trafficking using bioluminescence resonance energy transfer, and fluorescence activated cell sorting.

[0119] Inhibition or partial inhibition of the CCR2 pathway and / or AT1R caused by (i) ripagermanium or propagermanium, (ii) an AT1R blocker, or (iii) a combination of ripagermanium or propagermanium and an AT1R blocker can be measured using in vivo methods, including but not limited to measuring the cell and cytokine content of lung exudate, measuring lung function, including measuring the physical capacity of lung function using a spirometer-based test or measuring lung function output using blood gas or other biochemical indices, or improvement in functional gain, including clinical benefit measured using quantitative methods (such as a walking test) or qualitative methods (such as patient-reported outcome assessments). Inhibition or partial inhibition can be indicated by qualitative improvements in lung structure as measured by one or more of the above endpoints.

[0120] In a preferred embodiment, the overall efficacy of the pharmaceutical preparation is greater than the efficacy of the AT1R blocker or rapagem or propagem when either component is administered without the other. Thus, the combined preparation can be administered in a single dose (including subtherapeutic doses) or less frequently than either of the two components when administered as a single compound.

[0121] Preferably, the total efficacy of the pharmaceutical preparation is greater than the sum of the efficacy of the AT1R blocker and repagermanium or propagermanium when either component is administered without the other. More preferably, a synergistic effect in efficacy is observed when the AT1R blocker and repagermanium or propagermanium are administered simultaneously or sequentially.

[0122] Alternatively, the total efficacy of the pharmaceutical preparation is equal to the sum of the efficacy of the AT1R blocker and repagermanium or propagermanium (when either component is administered without the other). As a further preferred embodiment of this alternative, an additive effect of efficacy is observed when the AT1R blocker and repagermanium or propagermanium are administered simultaneously or sequentially.

[0123] In another alternative, the total efficacy of the pharmaceutical formulation is less than the sum of the efficacy of the AT1R blocker and repagermanium or propagermanium (when either component is administered without the other). In another embodiment, while the combined efficacy is less than the sum of the efficacy of the AT1R blocker and repagermanium or propagermanium (when each component is administered without the other), the treatment provides greater efficacy than monotherapy with either the AT1R blocker or repagermanium or propagermanium administered alone.

[0124] Preferably, the two components are administered simultaneously (e.g., two tablets taken together, or a single tablet formulated with each component) or sequentially (e.g., one tablet taken after the other). The doses of each component can be taken together (simultaneously), or sequentially and within seconds, minutes, days, weeks or months of each other.

[0125] One component of the combination of the invention may already be administered to the subject, for example as a standard of care treatment. In this case, the second component of the combination of the invention is administered as the second component in therapy to provide a therapeutic combination of the invention.

[0126] Treatment

[0127] The present invention also provides a method for treating, improving or preventing kidney disease, the method comprising the following steps: administering to a subject:

[0128] a) A therapeutic formulation suitable for delivering 200 mg to 280 mg of rapagermanium or propagermanium per day.

[0129] The present invention also provides a method for treating, improving or preventing kidney disease, the method comprising the following steps: administering to a subject:

[0130] i) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0131] The present invention also provides a method for treating, improving or preventing kidney disease, the method comprising the following steps: administering to a subject:

[0132] i) a therapeutically effective amount of rapagermanium or propagermanium per day; and

[0133] ii) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0134] The present invention also provides a method for treating, improving or preventing kidney disease, the method comprising the following steps: administering to a subject:

[0135] i) a therapeutic formulation suitable for delivering 200 mg to 280 mg of rapagermanium or propagermanium per day; and

[0136] ii) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0137] The subject to be treated is preferably a mammal, including a human mammal.

[0138] Repagermanium and the AT1R blocker may be administered in the same dosage form or in separate dosage forms.

[0139] Repagermanium and / or AT1R blocker can be antibody inhibitors or blockers of the respective receptors. Repagermanium and AT1R blocker can be the same active agent, such as a bispecific antibody. Repagermanium and / or AT1R blocker can be pharmaceutically acceptable salts of Repagermanium and / or AT1R blocker.

[0140] Repagermanium and the AT1R blocker can be administered simultaneously or sequentially.

[0141] One component of the combination of the invention may have been administered to the subject as, for example, standard of care treatment. In this case, the second component of the combination of the invention is administered as the second component in the treatment to provide the therapeutic combination of the invention.

[0142] While not intended to be limited to any particular mode of action, in a preferred embodiment, rapagen has greater affinity and / or potency and / or efficacy when interacting with CCR2 or modulating its downstream pathway when CCR2 is associated with the angiotensin receptor AT1R. For example, CCR2 and the angiotensin receptor AT1R may be associated as a CCR2 / AT1R complex.

[0143] Preferably, the combination of the present invention provides a lower dose of AT1R blocker or rapagermanium than when either is used alone. For example, one or both of the AT1R blocker or rapagermanium may be provided at a subtherapeutic dose. This will help reduce the negative safety profile of AT1R or rapagermanium while having the same therapeutic benefit.

[0144] In another preferred embodiment, when rapagermanium and an AT1R blocker are administered to a subject simultaneously or sequentially, the affinity, potency and / or efficacy of the combination is greater than the affinity, potency and / or efficacy achieved when rapagermanium is not administered in combination with an AT1R blocker (whether simultaneously or sequentially). In an even more preferred embodiment, when rapagermanium and an AT1R blocker are administered to a subject in combination (whether simultaneously or sequentially), a synergistic effect (as measured by affinity, potency and / or efficacy) is achieved.

[0145] Although not intended to be limited to any particular mode of action, in a preferred embodiment, when the angiotensin receptor AT1R is associated with CCR2, the AT1R blocker has greater affinity and / or potency and / or efficacy when interacting with the angiotensin receptor AT1R. For example, CCR2 and the angiotensin receptor AT1R can be associated as a CCR2 / AT1R complex. In another preferred embodiment, when the AT1R blocker is administered to a subject simultaneously or sequentially with rapagemberger, the combined affinity, potency and / or efficacy is greater than the affinity, potency and / or efficacy achieved by the AT1R blocker when not administered in combination with rapagemberger (whether simultaneously or sequentially). In an even more preferred embodiment, when the AT1R blocker is administered to a subject in combination with rapagemberger (whether simultaneously or sequentially), a synergistic effect (measured by affinity, potency and / or efficacy) is obtained.

[0146] For purposes of the present invention, equal or greater affinity of an AT1R blocker for a CCR2-AT1R complex is considered an AT1R blocker affinity, wherein the affinity loss at the CCR2-AT1R complex does not exceed 3.5-fold compared to the affinity at AT1R.

[0147] deliver

[0148] The dosage forms provided herein may also include vials, cartridges, containers, tablets or capsules containing the pharmaceutical formulation of the present invention together with dosage instructions for administering the dosage form to a subject to treat, ameliorate or prevent a condition or disease.

[0149] The amount of each active ingredient that can be combined with a carrier material to produce a single dose will vary depending on the host to be treated and the specific mode of administration. For example, a formulation intended for oral administration to humans may contain about 0.5 mg to 1 g of each active compound and a suitable and convenient amount of carrier material, which may vary from about 5% to 95% of the total formulation. Dosage unit forms generally contain about 0.5 mg to 500 mg of active ingredient.

[0150] Preferably, the AT1R blocker is provided at a dose of 2 mg to 800 mg per day, provided in one or more doses. Even more preferably, the AT1R blocker is provided at a dose of 75 mg to 300 mg per day. For example, the AT1R blocker is irbesartan and is administered at a dose of 75, 150 or 300 mg per day, provided in one or more doses.

[0151] Preferably, rapagembergergum or propagembergergum is provided at 200 mg to 280 mg per day, in one or more doses. More preferably, rapagembergergum or propagembergergum is provided at a dose of 220 mg to 260 mg per day, more preferably 240 mg per day, in one or more doses.

[0152] The dosage of each active agent can be provided in a single dosage form or two separate dosage forms, and can include 2 mg to 800 mg of AT1R blocker and 200 mg to 280 mg of rapagem or propagem. The dosage of these two active substances can be provided in a single dosage form or two separate dosage forms, and can include (i) 2 mg to 800 mg of AT1R blocker per day, and (ii) 200 mg to 280 mg of rapagem or propagem. The AT1R blocker can be irbesartan, and the dosage form can include irbesartan at a daily dose of about 300 mg. Alternatively, the AT1R blocker is valsartan, administered at a dose of 80 mg, 160 mg or 320 mg per day, provided in one or more doses.

[0153] However, it should be understood that the specific dosage level for any particular subject will depend on a variety of factors, including the activity of the specific compound used, age, body weight, general health, sex, diet, time of administration, route of administration, rate of excretion, drug combination, and the severity of the specific condition or disease being treated.

[0154] In various aspects, the preparations of the present invention can be administered by injection, or prepared for oral, pulmonary, nasal or any other form of administration. Preferably, the preparations are administered by, for example, intravenously, subcutaneously, intramuscularly, intraorbitally, intraocularly, intraventricularly, intracranially, intracapsules, intraspinally, intracisternally, intraperitoneally, orally, rectally, vaginally, intranasally or by aerosol administration.

[0155] The mode of administration is at least suitable for the form of preparing the preparation on the one hand. The mode of administration that most effectively responds can be determined empirically, and the mode of administration described below is given as an example and does not limit the delivery method of the preparation of the present invention in any way. All preparations provided are commonly used in the pharmaceutical industry and are well known to qualified practitioners.

[0156] Oral dosage form

[0157] Oral solid dosage forms are contemplated for use herein, generally described in Martin, Remington's Pharmaceutical Sciences, 18th edition. (1990 Mack Publishing Co. Easton PA 18042) Chapter 89, which is incorporated herein by reference. Solid dosage forms include tablets, capsules, pills, lozenges or lozenges, cachets or pellets. In addition, liposomes or protein-like encapsulation can be used to formulate the preparations of the present invention (e.g., protein-like microspheres reported in U.S. Patent No. 4,925,673). Liposome encapsulation can be used and liposomes can be derived from various polymers (e.g., U.S. Patent No. 5,013,556). Marshall, Modern Pharmaceutics, Chapter 10, Banker and Rhodes et al., (1979) give a description of possible solid dosage forms of therapeutic agents, which are incorporated herein by reference. In general, the preparation will include the compound described as part of the present invention (or a chemically modified form thereof), and an inert component that allows protection from the gastric environment and release of bioactive materials in the intestine.

[0158] The oral dosage form of the present invention may be a liquid, suspension or other suitable dosage form that is delivered directly into a feeding tube of a patient who is in a coma and / or on a ventilator and is unable to swallow tablets or the like.

[0159] For the rapagen or AT1R blockers of the present invention, the release site can be the stomach, small intestine (duodenum, jejunum or ileum) or large intestine. Those skilled in the art have available formulations that will not dissolve in the stomach but will release the substance elsewhere in the duodenum or intestine. On the one hand, the harmful effects of the gastric environment will be avoided by protecting the formulation or by releasing the compound outside the gastric environment (e.g., in the intestine).

[0160] Coatings or coating mixtures may also be used for tablets that are not intended to protect the stomach. This includes, but is not limited to, sugar coatings or coatings that make the tablet easier to swallow. Exemplary capsules consist of a hard shell (e.g., gelatin) for delivery of dry therapeutic agents, i.e., powders; for liquid forms, a soft gelatin shell may be used. The shell material for cachets is in some aspects a thick starch or other edible paper. For pills, lozenges, molded tablets, or tablet grinders, moist massing techniques may also be considered, but are not limited to.

[0161] The present invention further provides an oral sustained-release pharmaceutical preparation comprising the therapeutically effective pharmaceutical preparation according to the present invention and a release-delaying agent.

[0162] In one aspect of the invention, the release delaying agent is a water-soluble, water-swellable and / or water-insoluble polymer. In particular, the water-soluble polymer is selected from ethylcellulose, hydroxypropylcellulose, hydroxypropylmethylcellulose, enteric coatings; and semipermeable membranes. In another aspect of the invention, the release delaying agent is a non-polymeric release delaying agent. More particularly, the non-polymeric release delaying agent is hydrogenated castor oil. According to conventional procedures known in the art, the preparation of the present invention can be ground or granulated and compressed into tablets or encapsulated into capsules.

[0163] To ensure complete resistance to gastric acid, a coating that is impermeable to at least pH 5.0 is used. Examples of more common inert ingredients used as enteric coatings are cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose phthalate (HPMCP), HPMCP 50, HPMCP 55, polyvinyl acetate phthalate (PVAP), Eudragit L30D, Aquateric, cellulose acetate phthalate (CAP), Eudragit L, Eudragit S and shellac. These coatings can be used as mixed films.

[0164] As used herein, the term "sustained release" refers to the gradual but continuous or sustained release of the therapeutic compound content over a relatively extended period of time after oral ingestion. Release may continue as the drug formulation passes from the stomach, through until the drug formulation reaches the intestine and thereafter. The phrase "sustained release" also means delayed release, in which the release of the therapeutic compound does not begin immediately when the drug formulation reaches the stomach, but is delayed for a period of time, for example, until the drug formulation reaches the intestine. After reaching the intestine, an increase in pH may trigger the release of the therapeutic compound from the drug formulation.

[0165] As used herein, the term "release delaying agent" refers to a substance that reduces the rate at which a therapeutic compound is released from a pharmaceutical formulation when taken orally. The release delaying agent can be a polymer or a non-polymer. Sustained release agents can be used according to any of several sustained release systems, including, for example, diffusion systems, dissolution systems, and / or osmotic systems.

[0166] In some aspects, the therapeutic agent is included in the formulation as fine multi-particulates in the form of granules or pellets, with a particle size of about 1 mm. In some aspects, the formulation of the material for capsule administration is a powder, a light compress, or even a tablet. In one aspect, the therapeutic agent can be prepared by compression.

[0167] Colorants and flavoring agents may optionally be included. For example, the compound may be formulated (eg, but not limited to, by liposome or microsphere encapsulation) and then further included in an edible product, such as a refrigerated beverage containing colorants and flavoring agents.

[0168] On the one hand, the volume of the therapeutic agent can be diluted or increased with an inert material. These diluents can include carbohydrates, especially mannitol, α-lactose, anhydrous lactose, cellulose, sucrose, modified dextran and starch. Certain inorganic salts can also be used as fillers, including tricalcium phosphate, magnesium carbonate and sodium chloride. Some commercially available diluents are Fast-Flo, Emdex, STA-Rx 1500, Emcompress and Avicell.

[0169] In other embodiments, disintegrants are included in the formulation of the therapeutic agent in a solid dosage form. Materials used as disintegrants include, but are not limited to, starch, including the commercial disintegrant Explotab based on starch. Also contemplated are sodium starch glycolate, Amberlite, sodium carboxymethylcellulose, super branched starch, sodium alginate, gelatin, orange peel, acid carboxymethylcellulose, natural sponge, and bentonite. Another form of disintegrant is an insoluble cation exchange resin. Powdered gums may also be optionally used as disintegrants and binders, including but not limited to powdered gums, such as agar, Karaya, or tragacanth. Alginic acid and its sodium salt may also be used as disintegrants.

[0170] Binders are expected to hold the therapeutic compound together to form a hard tablet and include, but are not limited to, materials from natural products such as gum arabic, gum tragacanth, starch, and gelatin. Other binders include, but are not limited to, methylcellulose (MC), ethylcellulose (EC), and carboxymethylcellulose (CMC). Polyvinylpyrrolidone (PVP) and hydroxypropylmethylcellulose (HPMC) are contemplated for use in alcohol solutions to granulate the therapeutic agent.

[0171] Anti-friction agents may optionally be included in the formulation of the therapeutic agent to prevent sticking during the formulation process. Lubricants may optionally be used as a layer between the therapeutic agent and the mold wall, these may include, but are not limited to: stearic acid, including its magnesium and calcium salts, polytetrafluoroethylene (PTFE), liquid paraffin, vegetable oils and waxes. Exemplary soluble lubricants may also be used, for example, including sodium lauryl sulfate, magnesium lauryl sulfate, polyethylene glycols of various molecular weights, and Carbowax 4000 and 6000.

[0172] Glidants may optionally be added which may improve the flow characteristics of the compound during formulation and aid in rearrangement during compression. Glidants may include, but are not limited to, starch, talc, fumed silica, and hydrated aluminosilicates.

[0173] To help the therapeutic agent dissolve into the aqueous environment, a surfactant may be added as a wetting agent in certain embodiments. The surfactant may include, for example, but not limited to, anionic detergents such as sodium lauryl sulfate, dioctyl sodium sulfosuccinate, and dioctyl sodium sulfonate. Cationic detergents may optionally be used and may include, but are not limited to, benzalkonium chloride or benzethonium chloride. A list of potential nonionic detergents that may be included in the formulation as a surfactant is lauryl alcohol 400, polyoxyethylene 40 stearate, polyoxyethylene hydrogenated castor oil 10, 50 and 60, glyceryl monostearate, polysorbate 40, 60, 65 and 80, sucrose fatty acid esters, methylcellulose and carboxymethylcellulose. When used, these surfactants may be present alone in the formulation of the compound or as mixtures in varying proportions.

[0174] Additives that increase absorption of the compound may be desirable. Such additives include the fatty acids oleic acid, linoleic acid, and linolenic acid.

[0175] Controlled release formulations may be needed. In some aspects, the compound can be incorporated into an inert matrix that allows release by diffusion or leaching mechanisms, i.e., gum. In some aspects, a slowly degenerated matrix can also be added to the formulation. Another controlled release form of this therapeutic agent is by a method based on the OROS™ treatment system (Alza Corp.), in which the drug is enclosed in a semipermeable membrane, allowing water to enter and push the drug out (due to osmosis) through a single small opening. Some enteric coatings also have a sustained release effect.

[0176] In other aspects, a mixture of materials may be used to provide an optimal film coating.Film coating may be performed, for example but not limited to, in a pan coater or in a fluidized bed or by compression coating.

[0177] Dosage regimen

[0178] It should be understood that in certain aspects, the formulations of the present invention can be administered as a single dose regimen, or preferably, in a multiple dose regimen. A multiple dose regimen is a regimen in which the primary delivery process may be 1 to 10 separate doses, followed by other doses optionally administered at subsequent time intervals required for maintenance or reinforcement of treatment. The dosage regimen will also be determined, at least in part, by the needs of the individual and the judgment of the practitioner.

[0179] Thus, the present invention provides tablets, capsules, liquids, suspensions or other oral dosage forms comprising the pharmaceutical formulations of the present invention.

[0180] The AT1R blocker and repagermanium or propagermanium may be delivered in the same formulation or in separate formulations.

[0181] The AT1R blocker and repagermanium or propagermanium may be in the same dosage form or in separate dosage forms.

[0182] The subject administered an AT1R blocker and rapagemator may have already received one of the active agents and may be administered the other component of the treatment of the invention in accordance with the invention.

[0183] use

[0184] The present invention provides use of 200 mg to 280 mg of rapagermanium or propagermanium per day for manufacturing a preparation for treating, improving or preventing kidney diseases.

[0185] The present invention provides a use of 200 mg to 280 mg of rapagermanium or propagermanium per day for treating, improving or preventing kidney diseases.

[0186] The present invention provides the use of a therapeutically effective amount of an AT1R blocker for manufacturing a preparation for treating, improving or preventing kidney diseases, wherein the affinity of the AT1R blocker to the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker to AT1R alone.

[0187] The present invention provides a use of a therapeutically effective amount of an AT1R blocker for treating, improving or preventing kidney diseases, wherein the affinity of the AT1R blocker to the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker to AT1R alone.

[0188] The present invention also provides the use of (a) a therapeutically effective amount of rapagermanium or propagermanium, and (b) a therapeutically effective amount of an AT1R blocker for manufacturing a preparation for treating, improving or preventing kidney diseases, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0189] The present invention also provides the use of (a) a therapeutically effective amount of rapagermanium or propagermanium, and (b) a therapeutically effective amount of an AT1R blocker for treating, improving or preventing kidney diseases, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0190] The present invention also provides a therapeutically effective amount of rapagermanium or propagermanium for use in a preparation for treating, improving or preventing kidney diseases, wherein at least one AT1R blocker and rapagermanium or propagermanium are administered to a subject simultaneously or sequentially.

[0191] The present invention also provides a therapeutically effective amount of rapagermanium or propagermanium for use in a preparation for treating, improving or preventing kidney diseases, wherein rapagermanium and a therapeutically effective amount of an AT1R blocker are administered to a subject simultaneously or sequentially, and the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

[0192] The therapeutically effective amount of the above-mentioned rapagermanium or propagermanium is preferably 200 mg to 280 mg of rapagermanium or propagermanium per day.

[0193] AT1R blockers having an affinity for the CCR2-AT1R complex equal to or greater than the affinity for AT1R alone may be selected from the list consisting of candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, valsartan and sparsentan. Preferably, the AT1R blocker is not EXP3174.

[0194] The therapeutically effective amount of the above AT1R blocker is preferably 2 mg to 800 mg per day.

[0195] Repagermanium or propagermanium and the AT1R blocker may be administered in the same dosage form or in separate dosage forms.

[0196] The rapagem or propagem and / or AT1R blocker can be an antibody inhibitor or blocker of the respective receptors. The rapagem or propagem and AT1R blocker can be the same active agent, such as a bispecific antibody. The rapagem or propagem and / or AT1R blocker can be a pharmaceutically acceptable salt of the rapagem or propagem and / or AT1R blocker.

[0197] Repagermanium or propagermanium and the AT1R blocker may be administered simultaneously or sequentially.

[0198] Reagent test kit

[0199] The present invention provides a kit for treating or preventing kidney disease, the kit comprising:

[0200] a) 200 mg to 280 mg per day of rapagermanium or propagermanium; and

[0201] b) Instructions for use.

[0202] The present invention also provides a kit for treating or preventing kidney disease, the kit comprising:

[0203] a) a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone;

[0204] b) Instructions for use.

[0205] The present invention provides a kit for treating or preventing kidney disease, the kit comprising:

[0206] a) a therapeutically effective amount of rapagermanium or propagermanium;

[0207] b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone; and

[0208] c) Instructions for use.

[0209] The therapeutically effective amount of the above-mentioned rapagermanium or propagermanium is preferably 200 mg to 280 mg of rapagermanium or propagermanium per day.

[0210] AT1R blockers having an affinity for the CCR2-AT1R complex equal to or greater than the affinity for AT1R alone may be selected from the list consisting of candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, valsartan and sparsentan. Preferably, the AT1R blocker is not EXP3174.

[0211] The contents of the kit may be lyophilized and the kit may additionally contain a suitable solvent for reconstituting the lyophilized components. The subcomponents of the kit will be packaged in separate containers, and associated with these containers may be a notice in the form prescribed by a governmental agency regulating the manufacture, use or sale of drugs or biological products, which notice reflects approval by the agency of manufacture, use or sale for human administration.

[0212] When the components of the kit are provided in the form of one or more liquid solutions, the liquid solution can be an aqueous solution, such as a sterile aqueous solution. For in vivo use, the expression construct can be formulated into a pharmaceutically acceptable injectable formulation. In this case, the container device itself can be an inhaler, syringe, pipette, dropper or other similar device, from which the formulation can be applied to the affected area of ​​the animal, such as the lungs, injected into the animal, or even adapted for and mixed with other components of the kit.

[0213] The components of the test kit can also be provided in dry or lyophilized form. When reagent or component are provided in dry form, reconstructed usually by adding suitable solvent. It is envisioned that the solvent can also be provided in another container device. Regardless of the quantity or type of container, the test kit of the present invention can also include or be packaged with an instrument for auxiliary injection / application or placement of the final compound formulation in an animal body. Such an instrument can be an inhaler, a syringe, a pipette, tweezers, a measuring spoon, an eye dropper or any such delivery tool of medical approval.

[0214] General

[0215] Those skilled in the art will appreciate that the invention described herein is susceptible to variations and modifications other than those specifically described. The present invention includes all such variations and modifications. The present invention also includes, individually or collectively, all steps, features, formulations and compounds mentioned or indicated in the specification, as well as any and all combinations or any two or more steps or features.

[0216] Each document, reference, patent application or patent cited in this article is expressly incorporated herein in its entirety by reference, which means that the reader should read and consider it as part of this article. The documents, references, patent applications or patents cited in this article are not repeated in this article only for brevity.

[0217] Any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein are incorporated herein by reference and may be used in the practice of the present invention.

[0218] The scope of the present invention is not limited by any specific embodiments described herein. These embodiments are for illustrative purposes only. Functionally equivalent products, formulations and methods are clearly within the scope of the present invention described herein.

[0219] The invention described herein may include one or more ranges of values ​​(e.g., size, displacement, and field strength, etc.). The range of values ​​will be understood to include all values ​​within the range, including the values ​​that define the range, and the values ​​adjacent to the range, which result in the same or substantially the same result as the values ​​immediately adjacent to the boundaries of the range. Therefore, unless otherwise indicated, the numerical parameters set forth in the specification and claims are approximate values ​​and may vary depending on the desired properties sought to be obtained by the present invention. Therefore, "about 80%" means "about 80%" as well as "80%". At a minimum, each numerical parameter should be interpreted according to the number of significant figures and ordinary rounding methods.

[0220] Throughout the specification, unless the context requires otherwise, the word "comprises" or variations such as "comprised" or "comprising" will be understood to imply the inclusion of the stated integer or groups of integers, but not the exclusion of any other integer or groups of integers. It should also be noted that in this disclosure, particularly in the claims and / or paragraphs, terms such as "comprises" or variations such as "comprised" or "comprising" may have the meanings ascribed to it in U.S. patent law; for example, they may mean "includes," "included," "including," and the like; and terms such as "consisting essentially of" and "consists essentially of" have the meanings ascribed to them in U.S. patent law, for example, they allow elements not expressly listed, but exclude elements found in the prior art or that affect the basic or novel characteristics of the invention.

[0221] Other definitions of selected terms used herein can be found in the detailed description of the present invention and apply throughout. Unless otherwise defined, all other scientific and technical terms used herein have the same meaning as those generally understood by those of ordinary skill in the art to which the present invention belongs. The term "active agent" may refer to one active agent or may include two or more active agents.

[0222] The following examples are used to more fully describe the manner of using the above invention, and to present the best mode contemplated for implementing various aspects of the invention. It should be understood that these methods are by no means intended to limit the true scope of the invention, but are presented for illustrative purposes. Example

[0223] Other features of the present invention are more fully described in the following non-limiting examples. This description is included only for the purpose of illustrating the present invention. It should not be construed as a limitation to the broad description of the present invention described above.

[0224] Example 1

[0225] Pharmacokinetic model of rapagermanium

[0226] method

[0227] Pharmacokinetic data were obtained from studies DMX-200-101, DMX-200-201, DMX-200-202, and DMX-200-203.

[0228] Table 2: Pharmacokinetic data

[0229]

[0230]

[0231] In all studies, blood samples were analyzed using liquid chromatography tandem mass spectrometry (LC-MS / MS). The method involved the addition of deuterated-PPG (d2-PPG) as an internal standard (IS) and sample preparation using chloroform liquid-liquid extraction. Samples were analyzed on an LC-MS / MS system consisting of a Shimadzu LC20AD and a Thermo Fisher Hypercarb column, using gradient elution and an API 4000 mass spectrometer. The mass spectrometer was operated in negative electrospray ionization (ESI) mode to monitor PPG and d2-PPG, respectively. 2- Ion transition from precursor to product of PPG. The lower limit of quantification (LLOQ) was 5 ng / mL.

[0232] The pharmacometry analysis was performed in several steps, driven by the suitability of clinical data for PK model development. 1. An initial structural population PK model was developed using data from healthy volunteers (Study 101). 2. The model was subsequently updated using sparse data from patients from Studies 202 and 203, and the effects of covariates were explored. 3. Model validation was performed. 4. Finally, the developed model was used to simulate the effects of covariates on key PK parameters as well as potential exposures.

[0233] SAS software (version 9.4) was used to prepare analytical data sets. Population PK analyses were performed using NONMEM (version 7.5.0) and the first-order conditional estimation (FOCE) method with interaction. PsN (version ≥5.0.0) was used to perform NONMEM runs and to run visual predictive checks (VPCs), sampling importance resampling (SIR), and automated stepwise covariate modeling (SCM). R software (version ≥4.0.2) was used for exploratory analyses, creation of goodness-of-fit (GOF) plots, and summary statistics. Simulations were performed using the R-based Campsis software application (version 1.1.0) provided by Calvagone.

[0234] NONMEM version 7.5.0 was used with GNU Fortran (GCC) compiler version 9.3.0, running on Ubuntu 20.04LTS, Linux kernel version 5.4.0-72-generic, Intel Xeon E5-2640 v3@8HT2.60GHz, VMWare ESXi 7.0u1 fault-tolerant platform, hosting a virtual management server with 8vcpu; compute nodes were Intel Xeon E5-2680 v4 14HT 2.40GHz. Fortran compiler optimization options were: -static-w-O3-ffast-math. All software was used in a validated environment.

[0235] In mixed-effects models, population parameters are classified as follows: Fixed-effect parameters θ (theta) are used to construct population parameters (such as Ka, CL, V, F, etc.), as well as certain parameters related to population parameters, including physiological or demographic variables (covariates) included in the analysis. Random-effect parameters η (eta) are used to describe the inter-individual variability (IIV) in the fixed-effect parameters and, if appropriately included in the model, can also be used to describe the inter-occasion variability (IOV). The Eta parameters are assumed to be normally distributed random variables with zero mean and variance-covariance matrix Ω (omega). The square roots of the diagonal elements of this matrix provide estimates of the IIV. Off-diagonal elements (if not fixed to zero) are usually transformed into correlations. Random-effect parameters ε (epsilon) are used to describe the residual variability. Residual variability includes within-individual error, analytical error, potential error due to model misspecification, and any other error not accounted for by the structural elements (such as θ and η). The residual variability parameters are assumed to be normally distributed random variables with mean zero and standard deviation σ (sigma).

[0236] Different structural models were combined with different residual models and, when necessary, different estimation methods to determine the most appropriate mixed effects model. Parameter estimation was performed using first-order conditional estimation (FOCE) with the interaction option, taking into account the interaction between the between-subject random effect η and the residual random effect ε. Assuming a log-normal distribution of the individual pharmacokinetic parameters, an exponential model was used to describe the inter-individual variability (IIV) of the model parameters:

[0237] PPmm=PPTTTT×ffηη

[0238] where PI is the individual parameter value, P TV is the typical population estimate of the parameter, and η is the individual deviation from the population estimate with mean 0 and variance ω2. Correlations between random effect parameters were investigated by estimating some selected off-diagonal elements of the omega matrix. Inter-occasion variability (IOV) of parameters F and CL / F was assessed to potentially explain variability associated with steady-state PK observations performed at completely different visits during the study. The data were modeled using a two-sided log-transformed (LTBS) approach, where residuals were included as additive errors on a logarithmic scale. Separate residual terms were explored between healthy subjects and patients.

[0239] The construction of the covariate model was exploratory. First, potential relationships between covariates and individual parameter estimates were explored graphically if the degree of eta-contraction in the parameters was reasonably low (<25%). As the model was intended for exposure simulations in children, it was decided to consider the association between body weight and PK parameters based on the allometric theory already present in the base model. For clearance and intercompartmental flow (Q), a fixed allometric exponent of 0.75 was used, while for the relationship between volume and body weight, an exponent of 1.0 was used. Automated stepwise covariate modeling (SCM) using the forward addition / backward deletion procedure implemented in PsN

[20] was applied to the base model for the full analysis data set. To improve the computational time of the SCM, PsN s N Taylor transformation was applied to generate a linearized form of the model, to which the covariate function was then applied. The final model of the SCM process was then rerun in its original, untransformed form. The following covariates were tested for association with CL and relative bioavailability (F) in the model: weight, BMI, age, race (if more than 5% of non-white participants), sex, liver and kidney function (AST, ALT, albumin, CRCL, eGFR), disease (equivalence study). In principle, the covariate values ​​at baseline were considered, but if changes in covariates over time also need to be considered in the covariate model, an assessment was made. The correlation between covariates was assessed graphically. If two or more covariates are highly correlated, the covariate with the greatest clinical / biological and practical relevance will be tested preferentially in the covariate analysis, while the other covariate will be discarded or tested only after the more relevant covariate is included in the model. For continuous covariates, linear or power functions were tested, as shown in the following equations:

[0240] P i =P TV ×(1+θ×(COVAR i -MED COVAR )); Linear function

[0241] Power function

[0242] Where Pi is the parameter estimate for the i-th patient, and the values ​​of the covariate (COVARi) are centered or scaled to the typical median of the covariate (MEDCOVAR). θ is the slope (exponential) of the parameter-covariate relationship. A binary covariate is included, as shown in the following figure:

[0243] P i =P TV ×(1+θ×CATCOVAR)

[0244] Where θ is the coefficient of the parameter-covariate relationship. CATCOVAR takes a value of 0 or 1 for the status (absent / present) of the covariate value for a particular individual. During SCM, a forward addition / backward deletion process was performed. Generally, in the forward selection process, each time a covariate is introduced into the model, only the covariate model relationships that are considered significant are considered for the next step. The covariate with the highest statistical significance is included first, and then the other significant covariates from the first step are retested. Similarly, the most significant covariate is then retained. This process is repeated until there is no further improvement in the model. In the backward deletion process, covariates are removed one at a time. The least significant parameter is removed from the model first, and this process is repeated until the covariate cannot be removed without significantly worsening the model adjustment. Forward covariate selection was performed using a p-value of p<0.05 (χp=0.05, v=12=3.84) as the selection criterion. Subsequently, backward deletion was performed using a p-value of p<0.01 (χp=0.01, v=12=6.63) as the selection criterion. After the covariate search is complete, the covariates included in the model are further evaluated for their clinical relevance and their contribution in explaining inter-individual variation. Clinical relevance is judged based on the change in predicted AUC at different values ​​of a given covariate (e.g., the percentage change in AUC for patients with high (low) body weight compared to patients with median weight). Small changes indicate that the covariate may have limited clinical relevance.

[0245] result

[0246] As a biomarker of renal function, clinical efficacy in reducing the protein to creatinine ratio was produced by administration of a 120 mg BID dose of rapagermanium, which resulted in a steady state AUC of approximately 15 ug.h / mL (range 5-25), as shown in Table 3.

[0247] Table 3: Individual steady-state exposures (AUC ) at a total daily dose of 240 mg in the subjects evaluated in the analysis 24hr )

[0248]

[0249] This specific dose and exposure of rapamycin is required for peak renal efficacy.

[0250] Example 2

[0251] ARB-CCR2 inhibitor combinations that inhibit G protein activation are no less potent than ARBs for the treatment of AT1R-CCR2 complexes Diseases for which AT1R-only ARBs are expected to be effective

[0252] The CCR2-AT1R complex has been previously identified as a target for the treatment of kidney disease. Inhibition of the CCR2 pathway and AT1R signaling is required for clinical effectiveness.

[0253] The present inventors have previously demonstrated that AT1R / CCR2 heteromers with ARBs provide a sustained and high degree of inhibition of inositol phosphate signaling. The present inventors have also demonstrated that the CCR2-AT1R complex leads to activation of Gαi protein and recruitment of β-arrestin.

[0254] However, it is unclear whether ARBs retain their potency in inhibiting Gαi activation or β-arrestin recruitment when acting in the CCR2-AT1R complex compared to AT1R alone. Understanding the ability of ARBs to inhibit AT1R in the context of a CCR2-AT1R complex is important because it is expected to affect clinical efficacy.

[0255] For example, the present invention demonstrates that AngII inhibits MCP-1-induced activation of the CCR2-AT1R complex to Gαi1 coupling. Blocking this AngII-mediated response using an ARB is expected to abolish the inhibition of MCP-1-induced Gαi1 signaling.

[0256] This experiment evaluated the efficacy of ARBs at AT1R alone, versus the efficacy of ARBs at costimulating the CCR2-AT1R complex, in a Gαi protein dissociation assay.

[0257] method

[0258] To determine whether ARBs retain their potency to inhibit Gαi activation, the potency of ARBs at AT1R alone was correlated with the potency of ARBs at costimulating CCR2-AT1R complexes obtained in a Gαi dissociation assay ( Figure 2 ).

[0259] The potency of ARBs at AT1R alone was obtained from public sources, such as the IUPHAR Pharmacology Database Guide and / or Michel et al. (2013). The potency of ARBs in costimulating the CCR2-AT1R complex was experimentally derived as described below.

[0260] HEK293FT cells were transiently transfected with plasmids encoding Gαi1-Nluc and CCR2-YFP hemagglutinin (HA)-tagged AT1R. 48 h after transfection, cells were incubated with substrate for 1 h and then pre-incubated with different concentrations of ARBs (candesartancilexetil, losartan, telmisartan, irbesartan, eprosartan, EXP3174, valsartan, olmesartan medoximil, olmesartan, azilsartan kamedoxomil or candesartan) for 30 min. Cells were then treated with 100 nM AngII and 100 nM MCP-1, or vehicle- and ligand-induced BRET was measured by measuring sequential light emission at 400-475 nM and 520-540 nM. BRET signal was calculated by subtracting the ratio of 520-540 nm emission to 400-475 nm emission of the same cell sample treated with vehicle from the same ratio of a second aliquot of cells treated with ligand (ligand-induced BRET).

[0261] Then, GraphPad Prism (v9.3.1) was used to plot the ligand-induced BRET versus ARB concentration, and the sigmoid concentration response curve was fitted using the nonlinear regression function of GraphPad Prism (v9.3.1) to obtain the potency (pIC 50 value).

[0262] HEK293FT cells were transiently transfected with plasmids encoding Gαi1-Rluc8, CCR2-YFP, and hemagglutinin (HA)-tagged AT1R to calculate sparsentan potency. 48 h after transfection, cells were incubated with substrate for 2 h, then pre-incubated with sparsentan (1 μM), and filtered light emission was measured sequentially for 1 second each in the "donor wavelength window" (410-490 nm) and the "acceptor wavelength window" (520-620 nm) for 30 min. Cells were then stimulated for another 1 h with 10 nM MCP-1 (CCL2) and different concentrations of AngII and filtered light emission was measured.

[0263] Ligand-induced BRET versus AngII concentration in the absence and presence of sparsentan (1 μM) were then plotted as sigmoidal concentration response curves using GraphPad Prism (v9.3.1), the data were fit using the nonlinear regression function of GraphPad Prism (v9.3.1), and sparsentan affinity estimates (pKB) were calculated as pKB as described in Furchgott ((1972) The classification of adrenoceptors (adrenergic receptors). Anevaluation from the standpoint of receptor theory, in Catecholamines, Handbook of Experimental Pharmacology (Blaschko H and Muscholl E eds) Vol 33, pp 283–335).

[0264] The efficacy of ARBs on costimulating CCR2-AT1R complexes was then compared to the efficacy of ARBs on AT1R using the linear regression function of GraphPad Prism (v9.3.1). Robust linear regression and outlier removal (ROUT) coefficients set to Q = 1 were then used to compare the efficacy of ARBs on AT1R. Figure 2 The data in were analyzed to identify outliers with lower than expected power.

[0265] ARBs with a potency ≥3-fold lower than expected at the CCR2-AT1R complex compared with AT1R alone were considered pharmacologically relevant and analyzed by one-sample t-test to assess statistical significance ( Figure 3 ).

[0266] Figure 4 The effects of a combination of ARBs and CCR2 pathway inhibitors on Gαi1 coupling to the CCR2-AT1R complex as measured by ligand-induced BRET are shown. HEK293FT cells were transiently transfected with plasmids encoding Gαi1-Rluc8 and CCR2-YFP in the presence of hemagglutinin (HA)-tagged AT1R. 48 h after transfection, cells were used to generate agonist-induced BRET signal data in live cells stimulated with 100 nM MCP-1 (CCL2) or 100 nM MCP-1 (CCL2) and 100 nM AngII in the presence of irbesartan, CCR2 pathway inhibitors, or irbesartan and CCR2 pathway inhibitors.

[0267] After adding the BRET substrate, BRET detection was performed in living cells by measuring the sequential light emission at 400-475 nm and 520-540 nm before and after the addition of the agonist. The BRET signal was calculated by subtracting the same ratio of the 520-540 nm emission to the 400-475 nm emission of the second aliquot of cells treated with the ligand (ligand-induced BRET) from the same ratio of the same cell sample treated with the vehicle. Activation of CCR2 resulted in a decrease in the BRET ratio, indicating that activation resulted in a change in the conformation of the Gαi1 protein pre-assembled with CCR2. Therefore, the data are expressed as "ligand-induced BRET decrease (percent of control)", so that the change in BRET signal observed with 100 nM MCP-1 is assigned to 100%, while no change in BRET signal is assigned to 0%.

[0268] result

[0269] Values ​​for AT1R potency alone are derived from the IUPHAR Pharmacology Guidelines (Alexander et al. (2021) The Concise Guide to Pharmacology 2021 / 22 Br J Pharmacol. 2021.178 Suppl 1: S1-S513 and / or Michel et al. (2013) A Systematic Comparison of the Properties of Clinically Used Angiotensin II Type 1 Receptor Antagonists Pharmacol Rev 65: 809–848). These values ​​represent the expected potency of the ARB on the co-stimulatory CCR2-AT1R complex. Experimental potency values ​​are reported as pIC50 or pKB values. The pIC50 value is the negative logarithm of the molar concentration of the ARB required to inhibit 50% of the BRET change mediated by the co-stimulatory CCR2-AT1R complex. The experimental potency value reported as pKB is the negative logarithm of the molar concentration that would occupy 50% of the receptor at equilibrium in the absence of agonist.

[0270] Comparison of the potency of ARBs against AT1R alone and the co-stimulatory CCR2-AT1R complex ( Figure 2 ) and Table 4, we found a good linear regression R 2 =0.97, indicating that there is a good correlation between the potency of ARBs in costimulating the CCR2-AT1R complex and AT1R alone.

[0271] This data indicates that when acting at the CCR2-AT1R complex, the potency of most ARBs is within 3.5-fold of that of ARBs acting at the AT1R receptor alone. This supports the use of ARBs with uncompromised potency when targeting the CCR2-AT1R complex to treat disease.

[0272] In contrast, outlier analysis revealed that EXP3174 had lower than expected potency in inhibiting Gαi protein activation mediated by the co-stimulatory CCR2-AT1R complex compared to the potency of EXP31471 at AT1R alone.

[0273] The potency of X3147 in the CCR2-AT1R complex was found to be 4.07-fold lower than that in AT1R alone, which was statistically significant ( Figure 3 ; p<0.01, one-sample t-test). This data indicates that the efficacy of ARBs acting on the CCR2-AT1R complex is not significant and cannot be considered to be the same as the efficacy on AT1R alone. ARBs with reduced efficacy on the CCR2-AT1R complex, such as EXP3174, are not preferred for treating diseases targeting the CCR2-AT1R complex and are expected to have reduced efficacy.

[0274] Figure 4 The changes in ligand-induced BRET after stimulation of cells expressing the CCR2-AT1R complex with vehicle, CCL2 (100 nM), or CCL2 (100 nM) and AngII (100 nM) are shown. In cells expressing CCR2-AT1R co-stimulated with CCL2 (100 nM) and AngII (100 nM), Gαi1 protein activation was inhibited by the combination of ARB and CCR2 pathway inhibitor. It can be expected that the loss of ARB potency at the CCR2-AT1R complex will affect the inhibitory efficacy compared to AT1R alone.

[0275] Figure 5 and Table 4 demonstrate the expected efficacy of the combination of an ARB with the CCR2 pathway inhibitor, rapagem, in inhibiting activation of Gαi1 protein in CCR2-AT1R expressing cells co-stimulated with CCL2 (100 nM) and AngII (100 nM).

[0276] Table 4: Inhibitory potency or affinity (pIC) of ARBs at AT1R alone or at co-stimulatory AT1R+CCR2 complexes 50 / pKb)

[0277]

[0278] 1. From IUPHAR Pharmacology Guidelines and / or Michel et al. (2013). 2. ARB potency (pIC50) for inhibiting Gα-protein dissociation in CCR2 / Luc-AT1R complex co-stimulated with AngII and CCL2. 3. Predictive potency of ARBs for inhibiting Gα-protein dissociation in CCR2 / Luc-AT1R complex co-stimulated with AngII and CCL2 in the presence of rapamermanium. ^; Data for fimasartan are predictive. $, Data from Choung et al., 2018 Discovery of the bifunctional modulator of angiotensin II type 1 receptor (AT1R) and PPARγ derived from the AT1R antagonist, Fimasartan. Bioorganic & Medicinal Chemistry Letters (28), 19: 3155-3160. #, Sparsentan affinity (pKb) in AT1R-CCR2 complex. **, p < 0.01 one-sample t-test, the efficacy is significantly reduced compared with AT1R alone.

Claims

1. A therapeutic formulation suitable for delivering a daily dose of 200 mg to 280 mg of rapagermanium or propagermanium.

2. A therapeutic formulation suitable for delivering a daily dose of a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

3. A therapeutic formulation suitable for delivering a daily dose of: a) a therapeutically effective amount of rapagermanium or propagermanium; and b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

4. The preparation of claim 3, wherein the daily dose of rapagermanium or propagermanium is 200 mg to 280 mg.

5. The formulation of claim 2 or 3, wherein the AT1R blocker is selected from the list consisting of candesartan, eprosartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, fimasartan and sparsentan.

6. The formulation of claim 2 or 3, wherein the daily dose of the AT1R blocker is 2 mg to 800 mg.

7. A dosing regimen comprising administering a daily dose of 200 mg to 280 mg of rapagermanium or propagermanium.

8. A dosing regimen comprising administering a daily dose of a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

9. A dosing regimen comprising administering a daily dose of: a) a therapeutically effective amount of rapagermanium or propagermanium; and b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

10. A method for treating, improving or preventing kidney disease, comprising administering to a subject the following steps: a) A therapeutic formulation suitable for delivering 200 mg to 280 mg of rapagermanium or propagermanium per day.

11. A method for treating, improving or preventing kidney disease, comprising administering to a subject the following steps: a) A therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

12. A method for treating, improving or preventing kidney disease, comprising administering to a subject the following steps: a) a therapeutically effective amount of rapagermanium or propagermanium per day; and b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

13. Use of 200 mg to 280 mg of rapagermanium or propagermanium per day for the manufacture of a preparation for treating, improving or preventing kidney disease in a subject.

14. Use of 200 mg to 280 mg of rapagermanium or propagermanium per day for treating, ameliorating or preventing kidney disease in a subject.

15. Use of a therapeutically effective amount of an AT1R blocker for the manufacture of a preparation for treating, ameliorating or preventing a kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

16. Use of a therapeutically effective amount of an AT1R blocker for treating, ameliorating or preventing a kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

17. Use of (a) a therapeutically effective amount of rapagermanium or propagermanium, and (b) a therapeutically effective amount of an AT1R blocker for the manufacture of a preparation for treating, ameliorating or preventing a kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

18. Use of (a) a therapeutically effective amount of rapagermanium or propagermanium, and (b) a therapeutically effective amount of an AT1R blocker for treating, ameliorating or preventing a kidney disease in a subject, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

19. A therapeutically effective amount of rapagermanium or propagermanium for use in a preparation for treating, ameliorating or preventing kidney disease in a subject, wherein rapagermanium is administered to the subject simultaneously or sequentially with a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone.

20. A therapeutically effective amount of an AT1R blocker having an affinity for a CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone, for use in a formulation for treating, ameliorating or preventing a kidney disease in a subject, wherein the at least one AT1R blocker is administered to the subject simultaneously or sequentially with rapagemator or propagemator.

21. A kit for treating or preventing a kidney disease in a subject, the kit comprising: a) 200 mg to 280 mg per day of rapagermanium or propagermanium; and b) Instructions for use.

22. A kit for treating or preventing a kidney disease in a subject, the kit comprising: a) a therapeutically effective amount of an AT1R blocker, wherein the affinity of the AT1R blocker for the CCR2-AT1R complex is equal to or greater than the affinity of the AT1R blocker for AT1R alone; b) Instructions for use.

23. A kit for treating or preventing a kidney disease in a subject, the kit comprising: a) a therapeutically effective amount of rapagermanium or propagermanium; b) a therapeutically effective amount of an AT1R blocker having an affinity for the CCR2-AT1R complex that is equal to or greater than the affinity of the AT1R blocker for AT1R alone; and c) Instructions for use.

24. The dosing regimen of any one of claims 7 to 9, the method of any one of claims 10 to 12, the use of any one of claims 13 to 20 or the kit of any one of claims 21 to 23, wherein the rapagembergerm or propagembergerm is provided in a daily dose of 200 mg to 280 mg rapagembergerm or propagembergerm.

25. The dosing regimen of any one of claims 7 to 9, the method of any one of claims 10 to 12, the use of any one of claims 13 to 20 or the kit of any one of claims 21 to 23, wherein the AT1R blocker is selected from the list consisting of candesartan, eprosartan, fimasartan, irbesartan, losartan, olmesartan, telmisartan, valsartan, fimasartan and sparsentan.

26. The dosing regimen of any one of claims 7 to 9, the method of any one of claims 10 to 12, the use of any one of claims 13 to 20 or the kit of any one of claims 21 to 23, wherein the subject to be treated is a human mammal.

27. The dosing regimen of any one of claims 7 to 9, the method of any one of claims 10 to 12, the use of any one of claims 13 to 20 or the kit of any one of claims 21 to 23, wherein the renal disease is a renal disease associated with proteinuria.

28. The dosing regimen of any one of claims 7 to 9, the method of any one of claims 10 to 12, the use of any one of claims 13 to 20, or the kit of any one of claims 21 to 23, wherein the kidney disease is selected from the list consisting of focal segmental glomerulosclerosis (FSGS; including idiopathic (primary) FSGS, secondary FSGS, hereditary FSGS, and FSGS due to any other cause), renal fibrotic disorders, immunoglobulin A nephropathy (IgAN), Alport syndrome, chronic kidney disease including chronic kidney disease caused by diabetic nephropathy, renal insufficiency (diabetic and non-diabetic), and renal failure conditions including diabetic nephropathy, glomerulonephritis, scleroderma, glomerulosclerosis, proteinuria of primary kidney disease, and renovascular hypertension.

29. The dosing regimen of any one of claims 7 to 9, the method of any one of claims 10 to 12, the use of any one of claims 13 to 20 or the kit of any one of claims 21 to 23, wherein the AT1R blocker is not EXP3174.